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Abstract
Background: Brain-derived neurotrophic factor (BDNF) and its receptor Tropomysin-related kinase B (TrkB) are
commonly up-regulated in a variety of human tumors. However, the roles of BDNF/TrkB in hepatocellular
carcinoma (HCC) have been poorly investigated.
Methods: We evaluated the expressions of BDNF and TrkB in 65 cases of HCC by immunohistochemical staining.
Moreover, in human HCC cell lines of HepG2 and high metastatic HCCLM3, the secretory BDNF in supernatant was
measured by ELISA, the effects of BDNF neutralizing antibody or Trk tyrosine kinase inhibitor K252a on apoptosis
and invasion were examined by flow cytometry and transwell assay respectively.
Results: Higher expression of BDNF (63.1%) or positive expression of TrkB (55.4%) was found in HCC specimens,
which was significantly correlated with multiple and advanced stage of HCC. BDNF secretory level in HCCLM3 was
higher than that in HepG2 cells. Both anti-BDNF and K252a effectively induced apoptosis and suppressed invasion
of HepG2 and HCCLM3 cells.
Conclusions: These findings suggested that BDNF/TrkB are essential for HCC cells survival and invasion. BDNF/TrkB
signaling should probably be an effective target to prevent HCC advancement.
Background
Hepatocellular carcinoma (HCC) is a leading cause of can-
cer death worldwide, and the presense of intraheptatic
metastases at the time of surgery has been regarded as the
main causes of recurrence [1]. The cancer cells readily dis-
seminate via portal venous branches and patients with
multiple tumor nodules in liver are proved to have poor
prognosis [2]. Multiple hepatocellular carcinoma is usually
regarded as HCC with multiple tumor nodules, clinically
classified as either intrahepatic metastasis or multicentric
carcinogenesis [3]. Tumor cells’ invasion into blood vessels
and survival inside are essential to a successful metastasis
in liver, resulting in the formation of intrahepatic metas-
tases [4]. However, the key points have not been well
elucidated, and the investigation of mechanisms for multi-
ple HCC may improve the prognosis of this severe disease.
Brain-derived neurotrophic factor (BDNF) is a member
of nerve growth factor family, playing an important role in
supporting survival and growth of neurons. Tropomysin-
related kinase B (TrkB) is the primary receptor of BDNF,
which functions as a tyrosine kinase. BDNF and TrkB are
up-regulated in a variety of primary human tumors,
including neuroblastoma [5], breast [6], bladder [7] and
ovarian [8] cancers. In gastric cancer, a high level of TrkB
expression was predicted for distant metastases and poor
prognosis [9]. TrkB overexpression was also found in
highly metastatic pancreatic cancer cells, which was pre-
sumed to mediate the clinical features of aggressive growth
and metastasis of pancreatic cancer [10]. When activated
by BDNF, TrkB induces the activation of downstream sig-
naling molecules, such as Akt [11,12] and ERK [13,14],
which elicits the differential regulation of various cellular
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any medium, provided the original work is properly cited.activities, like cell proliferation [15], differentiation [16],
apoptosis [17], and invasion [18]. TrkB signaling promotes
cell survival in an anchorage-independent manner [19]. In
HCC, the expressions of BDNF and TrkB were found up-
regulated in detached HCC BEL7402 cell aggregations,
which were able to resistant to detachment-induced apop-
tosis [20].
Despite the increasing evidence of BDNF and TrkB on
tumor progression, whether they are involved in multi-
ple HCC has not yet been determined. In the present
study, the expressions of BDNF and TrkB in HCC speci-
mens were examined, and by neutralizing BDNF or inhi-
biting TrkB kinase activity in HCC cell lines to observe




A total of 65 HCC patients who had therapeutic resection
from January 2006 to January 2011 were enrolled in this
study. This study was approved by the Medical Research
Ethics Committee of China Medical University and the
informed consent was obtained from all patients. All of
the enrolled patients underwent curative surgical resection
without having chemotherapy or radiation therapy. For-
malin-fixed paraffin-embedded sections of tumor were
stained routinely with hemat o x y l i na n de o s i n( H E ) ,a n d
reviewed by two senior pathologists in order to determine
the histological characteristics and tumor stage according
to the AJCC/UICC TNM staging system (2003, Edit 6).
Clinicopathological information including tumor distribu-
tion (solitary or multiple nodules), differentiation, stage
a n dl y m p hn o d em e t a s t a s i sw a so b t a i n e df r o mp a t i e n t
records, and listed in additional file 1.
Immunohistochemistry
65 paraffin sections of HCC were deparaffinized and rehy-
drated routinely. The sections were incubated overnight at
4°C with primary rabbit polyclonal antibody detecting
BDNF (1:100) or TrkB (1:50, both from Santa Cruz, USA),
following 3% H2O2 and 5% goat serum treatment at 37°C
for 30 min after antigen recovery. Then they were incu-
bated with second antibody and streptavidin-peroxidase
(SP) complex for 30 min (SP kit, Maixin, China), and
visualized with 3,3’-diaminobenzidine (DAB, Maixin,
China). All the immunoreactions were separately evalu-
ated by two senior pathologists. Cells with brown particles
appearing in cytoplasm or cell membrane were regarded
as positive. The intensity of BDNF immunostaining (1 =
weak, 2 = intense) and the percentage of positive tumor
cells (0-5% = 0, 6-50% = 1, ≥51% = 2) were assessed in at
least 5 high power fields (×400 magnification) [7]. The
scores of each tumorous sample were multiplied to give a
final score of 0, 1, 2, or 4, and the tumors were finally
determined as negative: score 0; lower expression: score ≤
2; or higher expression: score 4. The percentage of TrkB
positive tumor cells was assessed in at least 5 high power
fields (×400 magnification), and >10% was regarded as
positive sample [21].
Cells culture and treatments
Human HCC cell lines HepG2 and HCCLM3 (with high
metastatic potential) were purchased from KeyGen
(China). HepG2 cells were grown in RPMI-1640 (Invitro-
gen, USA) and HCCLM3 cells were cultured in DMEM
(high glucose, Invitrogen, USA) supplemented with 10%
FBS, in incubator with 5% CO2 at 37°C. To neutralize
secretory BDNF in culture supernatant for subsequent stu-
dies, cells (80-90% confluence) were treated with anti-
BDNF antibody (20 μg/ml, Santa Cruz, USA) for 24 h. To
interfere with receptor tyrosine kinase signaling, cells were
also treated by Trk tyrosine receptor kinase inhibitor
K252a (0.1 μM, Sigma, USA) for 24 h. Cells treated were
used for apoptosis or invasion assays as described below.
The examinations were repeated at least three times.
Elisa
Human BDNF Quantikine™ ELISA kit purchased from
R&D Systems was used in this study. HepG2 and
HCCLM3 cells were cultured for 24 h before the super-
natant was collected by centrifugation. BDNF secretion
was measured using ELISA. In brief, 50 μlo fs a m p l e so r
standard was added to the microplate wells with 100 μl
assay diluent and incubated at room temperature for 2 h,
and 100 μl of BDNF conjugate was added. Incubation
was continued at room temperature for 1 h. Microplates
were washed and developed using 200 μlo fs u b s t r a t e
solution. Then the optical density was read at 450 nm
and wavelengh correction was set to 570 nm using a
microplate reader.
Cell apoptosis assay
The cell apoptosis was examined by flow cytometry
u s i n ga nA n n e x i nV - F I T Ca p o p t o s i sd e t e c t i o nk i t( B D ,
USA), following the manufacturer’s protocol. Cells were
washed twice in ice-cold PBS and resuspended in 1 ×
binding buffer (1 × 10
6/ml). Cells of 100 μl( 1×1 0
5)
were gently mixed with 5 μl Annexin V-FITC and 5 μl
PI, and then incubated for 15 min at room temperature
away from light. After supplemented another 400 μl1×
binding buffer, cell apoptosis was detected in flow cyt-
ometer. Data are representative of three individual
experiments.
Cell invasion assay
The cell invasion assay was performed using a 24-well
Transwell chamber (Costar, USA). At 24 h following
anti-BDNF treatment, cells (1 × 10
4) were detached and
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precoated with Matrigel (BD, USA) and cultured in
serum-free medium for 24 h. Cells were allowed to
migrate towards medium containing 10% FBS in the bot-
tom chamber. The non-migratory cells on the upper
membrane surface were removed with a cotton tip, and
the migratory cells attached to the lower membrane sur-
face were fixed with 4% paraformaldehyde and stained
with crystal violet. The number of migrated cells was
counted in 5 randomly selected 200× power fields under
microscope. Data presented are representative of three
individual wells.
Statistical analysis
T h eS P S S1 3 . 0s o f t w a r ew a sa p p l i e dt oc o m p l e t ed a t a
processing. c2-test was applied to analyze the correla-
tions between BDNF or TrkB expression and clinico-
pathological characteristics. T-test was used to evaluate
the difference of BDNF secretion between HepG2 and
HCCLM3 cells. One-way ANOVA was used to compare
the differences between cells with various treatments.
All data were represented as mean ± SD and results
were considered statistically significant when the p-value
was less than 0.05.
Results
The expressions of BDNF and TrkB in 65 cases of HCC by
immunohistochemistry
BDNF was expressed in 57 (87.7%) HCC samples. We
considered that 41 (63.1%) cases of HCC were higher
expression (scores of 4) and 24 cases (36.9%) were lower
expression (scores of 0, 1 or 2), including negative ones, as
described in Materials and methods. The positive expres-
sion rate of TrkB in HCC tissues was 55.4% (36/65), and
44.6% were negative (26/65), as described in Materials and
methods. Since BDNF/TrkB have been reported to facili-
tate survival and metastasis of tumor cells [22], the asso-
ciation between BDNF or TrkB expressions and the
presence of intrahepatic dissemination at the time of
resection was analyzed statistically in the present study.
More cases of intrahepatic multiple tumors were found in
HCCs with BDNF higher expression (p = 0.002). Likewise,
HCCs with negative TrkB tended to be solitary tumors
(p = 0.049). In addition, patients with more BDNF or posi-
tive TrkB expression had advanced stage of HCC (p =
0.005, p = 0.013). Moreover, a significant difference of
BDNF, not TrkB expression was detected between var-
iously differentiated HCCs (p = 0.036), and between HCCs
with or without lymph node metastasis (p = 0.016). Sam-
ples of BDNF and TrkB expression in HCCs are shown in
Figure 1. The correlations of BDNF or TrkB expression
and clinicopathological characteristics are shown in
Table 1 and 2.
The secretion of BDNF in HepG2 and HCCLM3 cells by
ELISA
BDNF is a cytokine secreted by a few human cancers,
supporting growth and survival of tumor cells [23]. To
explore whether HCC cells express BDNF secretorily,
BDNF in the supernatant of HepG2 and HCCLM3 cells
was examined by ELISA assays. The amounts of BDNF
produced extracellularly by HepG2 and HCCLM3 cells
were 88.6 ± 14.4 pg/ml and 138.4 ± 22.2 pg/ml, respec-
tively (p = 0.031), which was shown in Table 3. This
result showed that HCCLM3 cells had more BDNF pro-
duction, which probably correlated with its high meta-
static potential.
Anti-BDNF or K252a promoted cell apoptosis
It was demonstrated BDNF/TrkB protected various tumor
cells from apoptosis [24]. To investigate a positive role of
BDNF/TrkB in HCC cell survival, apoptosis was examined
after anti-BDNF or K252a treatment using Annexin
V-FITC assay by flow cytometry. The apoptotic rates of
control, anti-BDNF and K252a treated HepG2 at 24 h
time point were 5.29 ± 0.54%, 20.21 ± 1.54%, 18.39 ±
0.83%, respectively (p = 0.000, Figure 2). And the apoptotic
rates of control, anti-BDNF and K252a treated HCCLM3
at 24 h time point were 10.88 ± 0.42%, 30.35 ± 1.60%,
31.37 ± 2.16%, respectively (p = 0.000, Figure 2). These
results suggested that neutralizing antibody specific for
BDNF or Trk tyrosine kinase inhibitor K252a against
TrkB probably antagonized the protection of BDNF/TrkB
for HCC cells.
Effect of anti-BDNF or K252a on cell invasion
To understand the potential signaling induced by
BDNF/TrkB that affects cell invasion, anti-BDNF or
K252a was used and the invasion of treated cells was
examined by Transwell assay. As shown in Figure 3, the
invasive numbers of control, anti-BDNF and K252a trea-
ted HepG2 at 24 h were 42.3 ± 2.5, 30.7 ± 2.1 and 33.3
± 1.5, respectively (P = 0.001). And the invasive num-
bers of control, anti-BDNF and K252a treated HCCLM3
cells at 24 h were 51.3 ± 3.2, 39.7 ± 1.5 and 42.7 ± 3.1,
respectively (P = 0.005). These results showed that both
anti-BDNF and K252a effectively interrupted the inva-
sion of HepG2 and HCCLM3 cells.
Discussion
Hepatocellular carcinoma is the most lethal malignancy
in many countries, and the incurable feature is mainly
due to the advanced stage of disease with metastasis at
presentation. The intrahepatic dissemination of tumor
cells is common in HCC patients with poor prognosis.
It is rather necessary to clearly elucidate the molecular
mechanisms that promoted HCC metastasis. BDNF and
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Page 3 of 8Figure 1 BDNF and TrkB expressions in HCC by immunohistochemistry. A and B, high BDNF and TrkB immunoreactivity in multiple HCC. C
and D, positive BDNF and TrkB immunostaining in solitary HCC. Original magnification: all ×400.







Distribution Solitary 10 15 *0.002
Multiple 31 9
Differentiation Well 23 7 *0.036
Moderate-poor 18 17
Stage I+II 7 12 *0.005
III 34 12







* = statistically significant difference.
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tate apoptosis resistance and metastatic tumor cells sur-
vival [25]. Aiming at interfering BDNF/TrkB signaling
may be helpful in the progression of effective anticancer
strategies [26,27].
In the present study, the expressions of BDNF and TrkB
were examined in 65 cases of HCC by means of immuno-
histochemistry to evaluate the involvement of BDNF/TrkB
in the progression of HCC. BDNF was found up-regulated
and TrkB was overexpressed in human malignancies
[21,28]. Our results showed that the expressions of both
BDNF and TrkB appeared higher in multiple HCCs than
those solitary tumors. A statistical difference in BDNF
immunoreactivity not TrkB was observed between well
and moderate-poorly differentiated HCCs. We also found
a significant correlation between higher BDNF expression
and lymph node metastasis. However, TrkB positive
expression was not found difference in HCCs with lymph
node metastasis or not. Moreover, BDNF and TrkB
expressions were correlated with clinicopathological stage,
and higher expressions of them in advanced HCCs were
detected. These findings suggested a potential role of
BDNF and TrkB in affecting intrahepatic dissemination of
HCC cells.
Then HepG2 and HCCLM3 cells were utilized to
assess the effects of BDNF neutralization or TrkB kinase
interruption on cell apoptosis and invasion. The secre-
tory BDNF was detected in supernatant of cultured
HepG2 and HCCLM3 cells. BDNF content in HCCLM3
cells was more than that in HepG2 cells, which probably
correlated with the high metastatic potential of
HCCLM3 cells. Specific neutralizing antibody has been
used in suppressing cytokine functions during variable
biological processes [29]. We found in this study that
cell apoptosis was significantly induced in anti-BDNF
treated cells, which indicated that BDNF was required
for supporting the survival of HepG2 and HCCLM3
cells. The involvement of BDNF in the invasion of
HepG2 and HCCLM3 cells was also confirmed that
invasive cells were evidently decreased by BDNF anti-
body. Studies have shown that inactivation of Trk by
tyrosine kinase inhibitors was correlated with more
apoptotic [30], or less invasive tumor cells [31], and
aiming at interfering TrkB activation might be helpful in
the development of effective anticancer therapies. K252a
is a selective inhibitor of the tyrosine protein kinase
activity of the trk family of oncogenes and neurotrophin
receptors [32]. In this study, apoptotic cells were
observed increasing after K252a treatment, which was
considered that TrkB activated by BDNF was partici-
pated in the survival of HepG2 and HCCLM3 cells.
Moreover, K252a used in this study also demonstrated a
critical role of TrkB kinase activity in BDNF-induced
invasion of HepG2 and HCCLM3 cells. Further investi-
gations should be carried out for the detailed signalings
downstream of BDNF/TrkB in regulating the survival
and invasion of HCC cells.
Taken together, our study confirmed that both BDNF
and TrkB were higher expressed in multiple HCCs,
which was positively correlated with tumor progression.
Secretory BDNF in supernatant of HCCLM3 cells with
high metastatic potential were much more than that in
HepG2 cells. Furthermore, HepG2 and HCCLM3 cells
treated with BDNF neutralizing antibody or Trk tyrosine
kinase inhibitor K252a showed increased apoptosis and
decreased invasion. Our data thus revealed an important
role of BDNF/TrkB in regulating survival and invasion
of HCC cells and probably provided new insight into
the inhibition of BDNF/TrkB signaling as a target of
anti-HCC therapies. Nevertheless, the signaling pathway
(s) downstream of BDNF/TrkB that involved in metasta-
sis of HCC required further studies.







Distribution Solitary 10 15 *0.049
Multiple 26 14
Differentiation Well 20 10 0.090
Moderate-poor 16 19
Stage I+II 6 13 *0.013
III 30 16







* = statistically significant difference.
Table 3 Secretion of BDNF in supernatant of HepG2 and
HCCLM3 cells by ELISA
Cells BDNF concentration (pg/ml) p value
HepG2 88.6 ± 14.4 *0.031
HCCLM3 138.4 ± 22.2
* = statistically significant difference.
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Page 5 of 8Figure 2 Anti-BDNF or K252a treatment promoted cell apoptosis. The apoptotic cells in anti-BDNF or K252a group were apparently
increased in HepG2 or HCCLM3, in contrast to those control cells. The results were indicated as mean ± SD of three individual tests.
Figure 3 Interruption of cell invasion by anti-BDNF or K252a treatment. The number of invasive cells in anti-BDNF or K252a group was
significantly reduced in HepG2 or HCCLM3, compared with that in control group. The values were mean ± SD of three replicates.
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Our data suggested that BDNF/TrkB supports the survi-
val of HCC cells, and seems to serve as a critical media-
tor in the progression of intrahepatic dissemination of
HCC cells, and prevention of BDNF/TrkB signaling
could be an effective way in HCC therapy.
Additional material
Additional file 1: Clinicopathological characteristics of 65 HCC
patients in detail. Distribution, differentiation, stage and lymph node
metastasis were included, as well as BDNF score and TrkB expression by
immunohistochemistry in HCC specimens, which were statistically
analyzed in Table 1 and Table 2.
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